GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg
Recalled by Guardian Drug Co. Inc.
Class II — moderate
Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Guardian Drug Co. Inc. has recalled GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on June 10, 2026 and was initiated on May 28, 2026. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg. The company behind the recall is Guardian Drug Co. Inc., based in Dayton, NJ. The FDA describes the product as: “GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg, 96 Chewable Tablets, Distributed by: Geiss, Destin & Dunn, inc., Peachtree City, GA, NDC 50804-129-22.”
Why was GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg recalled?
According to the FDA, the stated reason for the recall is: “Presence of foreign substance: small metallic particles in chewable tablets.” In plain terms, this recall relates to foreign material.
A foreign material recall means that pieces of something which should not be in food — such as metal, plastic, or glass — may be present. These can pose a choking hazard or cause injury. Recalls like these are issued to remove the affected product before anyone is hurt.
What should you do?
If you think you may have bought GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg, compare it against the product description and identifying codes (Lot #: 1276118, expires: JAN- 2029.) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Guardian Drug Co. Inc. or your local health authority.
About this recall
This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Full recall details
- Status
- Ongoing
- Date reported
- June 10, 2026
- Recall started
- May 28, 2026
- Distributed in
- NJ
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg recalled?+
According to the FDA: Presence of foreign substance: small metallic particles in chewable tablets.
How serious is this recall?+
Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
What should I do if I have GOODSENSE Extra Strength, Antacid TABLETS, Calcium Carbonate 750 mg?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0574-2026. Information last synced from the FDA on July 6, 2026.